メインナビゲーションにスキップ
検索にスキップ
メインコンテンツにスキップ
岡山大学 ホーム
English
日本語
ホーム
プロファイル
研究部門
研究成果
設備
活動
プレス/メディア
受賞
専門知識、名前、または所属機関で検索
Scopus著者プロファイル
市原 英基
講師
,
岡山大学病院
h-index
4956
被引用数
32
h 指数
Pureの文献数とScopusの被引用数に基づいて算出されます
2007
2024
年別の研究成果
概要
フィンガープリント
ネットワーク
研究成果
(151)
類似のプロファイル
(11)
フィンガープリント
Eiki Ichiharaが活動している研究トピックを掘り下げます。このトピックラベルは、この研究者の研究成果に基づきます。これらがまとまってユニークなフィンガープリントを構成します。
並べ替え順
重み付け
アルファベット順
Pharmacology, Toxicology and Pharmaceutical Science
Non Small Cell Lung Cancer
100%
Lung Cancer
98%
Epidermal Growth Factor Receptor
89%
Chemotherapy
40%
Epidermal Growth Factor Receptor Kinase Inhibitor
35%
Osimertinib
30%
Granulocyte Colony Stimulating Factor
29%
Immune Checkpoint Inhibitor
28%
Progression Free Survival
28%
Gefitinib
24%
Malignant Neoplasm
21%
Neoplasm
21%
Overall Survival
20%
Group Trial
18%
Afatinib
16%
Protein Tyrosine Kinase Inhibitor
13%
Disease
12%
Anaplastic Lymphoma Kinase
12%
Monotherapy
11%
Pembrolizumab
11%
Febrile Neutropenia
10%
Chemoradiation Therapy
10%
Cisplatin
10%
Alectinib
9%
Lung Adenocarcinoma
9%
Adverse Event
9%
Bevacizumab
9%
Transgenic Mouse
8%
Disease Exacerbation
8%
Lung Tumor
8%
Cancer Model
8%
Combination Therapy
8%
Observational Study
7%
Small Cell Lung Cancer
7%
Vandetanib
7%
Protein Tyrosine Kinase
7%
Erlotinib
7%
Interstitial Lung Disease
6%
Carboplatin
6%
Programmed Cell Death
6%
Infection
6%
Phase II Trials
6%
Pleura Effusion
5%
Median Survival Time
5%
Creatinine
5%
Acute Myeloid Leukemia
5%
Carcinogenesis
5%
Mouse
5%
Randomized Controlled Trial
5%
Microtubule Associated Protein
5%
Keyphrases
Non-small Cell Lung Cancer (NSCLC)
42%
Lung Cancer
28%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
27%
Epidermal Growth Factor Receptor
26%
Immune Checkpoint Inhibitors
21%
Osimertinib
20%
Okayama
17%
Cancer Study
16%
EGFR mutation
16%
Clinical Practice Guidelines
15%
Granulocyte Colony-stimulating Factor (G-CSF)
15%
Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor (EGFR-TKI)
15%
Non-small Cell Lung Cancer Patients
15%
Chemotherapy
12%
Primary Prophylaxis
12%
T790M
12%
Progression-free Survival
11%
Poor Performance Status
10%
Gefitinib
10%
Lung Adenocarcinoma
9%
Re-biopsy
9%
Re-administration
9%
Afatinib
8%
Bevacizumab
8%
Programmed Death-ligand 1 (PD-L1)
8%
Japan Society of Clinical Oncology
7%
Tumor
7%
Performance Status
7%
Overall Survival
6%
Interstitial Lung Disease
6%
Meta-analysis
6%
Nave
6%
Median Progression-free Survival
6%
Transgenic Mice
5%
Confidence Interval
5%
T790M mutation
5%
Renal Toxicity
5%
Nintedanib
5%
Rechallenge
5%
Clinical Oncology
5%
Anaplastic Lymphoma Kinase
5%
Immunochemotherapy
5%
Potential Influence
5%
Vandetanib
5%
Lung Cancer Model
5%
Systematic Meta-analysis
5%
Medicine and Dentistry
Non Small Cell Lung Cancer
56%
Lung Cancer
46%
Epidermal Growth Factor Receptor
29%
Systematic Review
23%
Granulocyte Colony Stimulating Factor
23%
Immune Checkpoint Inhibitor
21%
Clinical Oncology
18%
Neoplasm
15%
Meta-Analysis
14%
Lung Adenocarcinoma
13%
Computer Assisted Tomography
10%
Cisplatin
9%
Febrile Neutropenia
9%
Pembrolizumab
9%
Osimertinib
9%
Progression Free Survival
8%
Programmed Death 1 Ligand 1
8%
Exon
8%
COVID-19
7%
Overall Survival
6%
Biopsy
6%
Programmed Cell Death
6%
Tyrosine-Kinase Inhibitor
6%
Nivolumab
5%
Nephrotoxicity
5%
Gefitinib
5%
Epidermal Growth Factor Receptor Kinase Inhibitor
5%
Group Trial
5%
Chemoradiotherapy
5%
Small Cell Lung Cancer
5%
Cancer Model
5%
Prospective Cohort Study
5%
Acute Myeloid Leukemia
5%
Oncogene
5%
